COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England
View ORCID ProfileFreja C. M. Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O’Connell, Meera Chand, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2022.03.22.22272691
Freja C. M. Kirsebom
1UK Health Security Agency, London, United Kingdom
Nick Andrews
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
Julia Stowe
1UK Health Security Agency, London, United Kingdom
Samuel Toffa
1UK Health Security Agency, London, United Kingdom
Ruchira Sachdeva
Eileen Gallagher
1UK Health Security Agency, London, United Kingdom
Natalie Groves
1UK Health Security Agency, London, United Kingdom
Anne-Marie O’Connell
1UK Health Security Agency, London, United Kingdom
Meera Chand
1UK Health Security Agency, London, United Kingdom
3Guys and St Thomas’s Hospital NHS Trust, London, UK
Mary Ramsay
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
Jamie Lopez Bernal
1UK Health Security Agency, London, United Kingdom
2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
4NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom

Data Availability
All data produced in the present work are contained in the manuscript and supplementary appendix.
Posted March 24, 2022.
COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England
Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O’Connell, Meera Chand, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.03.22.22272691; doi: https://doi.org/10.1101/2022.03.22.22272691
COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England
Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O’Connell, Meera Chand, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.03.22.22272691; doi: https://doi.org/10.1101/2022.03.22.22272691
Subject Area
Subject Areas
- Addiction Medicine (240)
- Allergy and Immunology (521)
- Anesthesia (125)
- Cardiovascular Medicine (1419)
- Dermatology (158)
- Emergency Medicine (291)
- Epidemiology (10295)
- Gastroenterology (527)
- Genetic and Genomic Medicine (2629)
- Geriatric Medicine (254)
- Health Economics (497)
- Health Informatics (1733)
- Health Policy (789)
- Hematology (266)
- HIV/AIDS (565)
- Medical Education (273)
- Medical Ethics (83)
- Nephrology (289)
- Neurology (2461)
- Nursing (145)
- Nutrition (377)
- Oncology (1323)
- Ophthalmology (401)
- Orthopedics (146)
- Otolaryngology (237)
- Pain Medicine (168)
- Palliative Medicine (51)
- Pathology (343)
- Pediatrics (780)
- Primary Care Research (296)
- Public and Global Health (5007)
- Radiology and Imaging (893)
- Respiratory Medicine (681)
- Rheumatology (309)
- Sports Medicine (245)
- Surgery (298)
- Toxicology (45)
- Transplantation (140)
- Urology (108)